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doi:10.1016/j.ejvs.2009.12.014Abstract Background: Aortofemoral bypass(AFB), iliofemoral bypass(IFB), and aortoiliac en-
darterectomy(AIE) are the three most common techniques for anatomical open surgical revas-
cularisation for patients with aorto-iliac occlusive disease(AIOD), but the optimal method of
reconstruction is unknown.
Aims: To review and compare mortality, morbidity and short- and long-term patency rates for
AFB, IFB and AIE in patients with AIOD reported in the English language literature
Methods: A MEDLINE(1970e2007) and Cochrane Library search for articles relating to AFB, IFB,
AIE and AIOD was undertaken. Studies were included if: a) patency rates based on life-tables
were available, and b) patient/study characteristics were reported.
Results: 29 studies(5738 patients) for AFB, 11 studies(778 patients) for IFB and 11 studies(1490
patients) for AIE were included. Operative mortality was 4.1% for AFB, 2.7% for IFB and 2.7% for
AIE (p< 0.0001). Systemic morbidity was 16.0% for AFB, 18.9% for IFB and 12.5% for AIE
(p< 0.05). Overall 5-year primary patency rates were 86.3%, 85.3% and 88.3% for AFB, IFB
and AIE, respectively (pZ NS).
Conclusion: Aorto-iliac endarterectomy was associated with significantly lower peri-operative
morbidity and mortality rates compared with bypass grafting. All three techniques were
equally effective in terms of long-term patency.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.21 4242000.
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ty for Vascular Surgery. PublisheIntroduction
Open surgical reconstruction represents the evidence-
based treatment of choice for Trans-Atlantic Inter-Society
Consensus (TASC) II type-C and D aortoiliac lesions.1,2 Since
the pioneering work by dos Santos in the area of aortoiliac
endarterectomy, a variety of anatomical and extra-d by Elsevier Ltd. All rights reserved.
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Figure 1 Cumulative patency for patients who underwent Aortofemoral Bypass, Iliofemoral Bypass and Aortoiliac
Endarterectomy.
Table 1 Overview of patient demographics, risk factors,
peri-operative surgical and long-term outcomes.
AFB AIE IFB DTAF
Characteristics
No of Studies 29 11 11 2
No. of Subjects 5738 1490 778 174
No. of Limbs 7521 1971 789 192
Mean age (years) 58.8 58.7 61.6 e
Female/% 24.4 21.0 21.8 e
Claudication/% 64.3 70.9 52.7 e
Ischaemia/% 35.7 29.1 47.3 e
Risk factors
Smokers/% 89.9 95.0 77.9 e
Diabetes/% 17.4 10.9 15.6 e
IHD/% 41.4 28.9 42.1 e
Hypertensive/% 39.6 32.1 36.8 e
Surgical outcomes
Operative Mortality/% 4.1 2.7 2.7 4.6
Early Systemic
Morbidity/%
16.0 12.5 18.9 e
Early Local Morbidity/% 6.3 3.4 5.7 e
Early Graft-related
Morbidity or
intervention failure/%
3.1 3.8 4.2 4.5
Primary patency
Overall 5 yr patency/% 86.3 88.3 85.3 79.6
Patency for
Claudication/%
89.8 90.8 86.7 e
Patency for Ischaemia/% 79.8 81.7 74.1 e
Surgical Management of Atherosclerotic Aorto-Iliac Occlusive Disease 461anatomical open surgical arterial reconstructions have
been described for the management of patients with
symptomatic aorto-iliac occlusive disease (AIOD).3 The
most widely utilised anatomical open surgical reconstruc-
tions are: aortofemoral bypass (AFB), iliofemoral bypass
(IFB) and aortoiliac endarterectomy (AIE). Descending
thoracic aortofemoral bypass (DTAF) has also been
described but is predominantly reserved for patients in
which the aforementioned reconstructions are unsuit-
able.4,5 Bypass grafting is widely accepted as the anatom-
ical procedure of choice for AIOD and aortoiliac
endarterectomy has fallen out of favour with the majority
of vascular surgeons. To date, no comparative study has
been undertaken to determine the optimal method of
anatomical reconstruction for AIOD.
The aims of this study were a) to review and compare
the short- and long-term outcomes of AFB, IFB, AIE and
DTAF for the treatment of AOID and b) to provide an
evidence-based benchmark with which to compare the
results of established and evolving endovascular therapies.
Materials and methods
We performed a MEDLINE, EMBASE and Cochrane Central
Register of Controlled Trials (CENTRAL) databases search
looking for English language articles relating to AFB, IFB,
AIE, DTAF and AIOD between January 1970 and August 2007.
The terms aorta, iliac artery and aortoiliac were included
amongst others. These were linked with terms such as
reconstruction, revascularisation, bypass, endarterectomy,
atherosclerosis and occlusion. Further articles were iden-
tified by following MEDLINE links, by cross-referencing from
the reference lists of major articles and by following cita-
tions for these studies.
Table 2 Patient demographics of Aortofemoral Bypass studies.
Author Study years Patients Limbs Female
(%)
Mean
age (yr)
Claud
(%)
Isch
(%)
A(F/I)2 A(F/I)1 Other Iliac
(%)
Bowes10 1976e1990 26 52 54 59 65 35 26 0 0 13
Brewster52 1963e1977 341 657 27 58 56 44 316 25 0 29
Couch14 1972e1985 111 208 e e 68 32 97 14 0 e
Dunn15 1968e1979 192 384 28 60 64 36 192 0 0 3
Friedman16 1986e1989 60 120 37 68 67 33 60 0 0 58
Harris18 1979e1984 200 377 26 58 71 29 177 23 0 0
Jackson21 1992e2003 111 222 37 49 42 58 111 0 0 0
Jensen22 1979e1986 56 112 68 45 80 20 40 2 14 33
Johnson23 1965e1975 88 176 e 53 66 34 88 0 0 e
Lau26 1977e1998 94 176 12 58 39 61 82 12 0 0
Littooy27 1977e1988 224 440 1 59 63 37 216 8 0 2
Martinez28 1967e1977 376 752 33 58 72 28 376 0 0 0
Mason29 1980e1985 59 114 e 59 75 25 55 4 0 0
Meister30 1989e1992 150 300 9 59 66 34 150 0 0 0
Melliere31 1977e1996 108 108 8 e 72 28 0 108 0 0
Mingoli32 1973e1990 238 476 23 58 39 61 476 0 0 34
Mulcare33 1964e1975 114 228 32 e 54 46 114 0 0 50
Naylor34 1975e1984 241 476 29 60 71 29 235 6 0 0
Hsiang19 1970e1984 80 e 35 55 70 30 e e 0 0
Passman39 1988e1993 139 278 1 68 58 42 139 0 0 0
Piotrowski41 1975e1985 32 64 6 59 63 37 32 0 0 0
Prager42 1991e1998 149 298 30 59 67 33 149 0 0 0
Prediville43 1978e1989 145 285 e 64 30 70 140 5 0 0
Schneider45 1986e1991 119 238 36 61 45 55 119 0 0 0
Sladen46 1968e1980 100 196 29 59 100 0 96 4 0 0
Szilagy47 1954e1983 1748 3010 e e 66 34 1262 41 445 6
Timaran48 1996e2001 60 102 17 42 6 12 46
Van der Vliet49 1976e1987 350 700 18 59 80 20 350 0 0 e
Yamazaki51 1992e1995 27 40 7 70 78 22 13 14 0 e
All studies 5738 10 589 24 59 64 36 5153 272 471 9
462 K.W.H. Chiu et al.Studies reporting long-term primary patency data
following open anatomical repair of aorto-iliac occlusive
disease were included if a) the results for patients with
AIOD were reported separately; b) the primary patency
data were presented in a life-table format that met the
Society for Vascular Surgery/International Society for
Cardiovascular Surgery ISCVS/SVS criteria, using yearly orTable 3 Patient demographics of Iliofemoral Bypass studies.
Author Study years Patients Limbs Female (%
Cham13 1972e1986 105 105 15
Harrington17 1965e1991 68 68 48
Jorgensen24 1980e1982 62 62 35
Kalman25 1976e1985 50 50 38
Mason29 1980e1985 39 50 e
Melliere55 1977e1996 144 144 13
Ng35 1984e1990 72 75 19
Oliveira37 1981e1991 16 16 0
Perler40 e 21 22 29
Piotrowski41 1975e1985 17 17 29
Van der Vliet49 1976e1987 184 114 15
All studies 778 723 22smaller intervals, or such life-tables could be reconstructed
from the presented data; c) the patient demographics and
study characteristics were reported in sufficient detail to
allow for adjustment for the case-mix and the reporting
methods in the analysis; and d) the study cohort was
greater than 10 patients. In instances whereby more than
one publication from the same cohort was available, we) Mean Age (yr) Claud (%) Isch (%) IF Other
62 46 54 105 0
66 44 56 68 14
61 19 81 62 0
59 56 44 50 0
62 31 69 50 0
e 69 31 144 0
65 63 37 75 0
65 31 69 16 0
64 53 47 22 0
50 47 53 17 0
60 61 39 114 70
62 53 47 723 84
Table 4 Patient demographics of Aortoiliac Endarterectomy studies.
Author Study years Patients Limbs Female (%) Mean age (yr) Claud (%) Isch (%) AIFE IFE Other
Aguiar9 Not stated 71 128 24 57 59 41 107 21 0
Brewster52 1963e1977 241 448 27 58 56 44 448 0 0
Butcher12 Not stated 100 185 23 e 78 22 144 41 0
Inahara20 1962e1978 201 321 21 65 59 41 321 0 0
Melliere31 1977e1996 108 108 6 e 74 26 0 108 0
Naylor34 1974e1984 57 109 39 53 86 14 109 0 0
Hsiang19 1970e1987 45 e 35 55 70 30 45 0 0
Oertli2 1959e1972 415 514 15 58 81 20 84 430 0
Oskam38 1971e1990 94 163 29 52 85 15 163 0 0
Radoux44 1982e1995 98 121 8 57 71 29 0 121 0
Vitale50 1966e1988 60 70 40 67 65 35 0 70 0
All studies 1490 2167 21 59 71 29 1421 791 0
Surgical Management of Atherosclerotic Aorto-Iliac Occlusive Disease 463included only the most recent publication unless;
a) evidence was available that the patient population did
not overlap and b) the most recent publication was
unsuitable for data extraction or a more complete data set
was available from previous publications.Table 5 Patient risk factors for Aortofemoral Bypass
studies.
Author Risk factors
Smoker
(%)
Diabetes
(%)
IHD
(%)
HT
(%)
Bowes10 73 27 58 27
Brewster52 100 12 40 35
Couch14 77 14 46 53
Dunn15 e 9 29 41
Friedman16 73 22 50 50
Harris18 e 8 e e
Jackson21 98 22 29 63
Jensen22 e e e e
Johnson23 e e e e
Lau26 90 21 30 53
Littooy27 89 e 48 44
Martinez28 87 24 e 30
Mason29 e 21 57 e
Meister30 97 27 37 49
Melliere31 e 8 15 26
Mingoli32 88 31 62 54
Mulcare33 e e e e
Naylor34 e e e e
Hsiang19 86 11 33 29
Passman39 82 19 38 e
Piotrowski41 75 19 53 22
Prager42 88 22 e e
Prediville43 97 11 16 33
Schneider45 97 20 41 56
Sladen46 99 e e e
Szilagy47 e 18 47 35
Timaran48 83 21 60 62
Van der Vliet49 87 11 24 45
Yamazaki51 e e e e
All studies 90 17 41 40A proforma was used to extract the data from the arti-
cles; these data included study design, reporting methods,
patient risk factors, operative morbidity/mortality and
primary and secondary patency rates. The patient demo-
graphics, risk factors, and short- and long-term outcomes
used in this study were previously identified as relevant
factors by other studies.6,7
The definition of ‘peri-operative’ period varied between
studies, but was generally defined as within 30 days of the
index intervention. Thus, we defined operative mortality as
death within this period. A systemic complication was
defined as a dysfunction of one or more major organ systems
within 30 days of the index procedure. A local complication
was defined as a non-fatal complication limited to the site of
operation and occurring within 30 days of the index proce-
dure. Graft-related complicationwas defined as all non-fatal
damage or disease related to the graft including intervention
failures (i.e. failed procedures). For AIE, as no prosthetic
graft was used, we only collected data for intervention fail-
ures (i.e. failed endarterectomy).
In order to calculate primary patencies, data from the
studies needed to be presented or able to be converted to
a life-table format. In 49% of the studies (22/45), patencyTable 6 Patient risk factors for Iliofemoral Bypass
studies.
Author Risk factors
Smoker (%) Diabetes (%) IHD (%) HT (%)
Cham13 e 10 e 26
Harrington17 68 32 63 60
Jorgensen24 e 6 26 e
Kalman25 e 18 38 e
Mason29 e 26 69 e
Melliere55 e 11 20 19
Ng35 e 17 91 45
Oliveira37 100 25 44 63
Perler40 69 31 e 69
Piotrowski41 76 0 41 24
Van der Vliet49 83 15 28 44
All studies 78 16 42 37
Table 7 Patient risk factors for Aortoiliac Endarterectomy
studies.
Author Risk factors
Smoker (%) Diabetes (%) IHD (%) HT (%)
Aguiar9 99 17 27 48
Brewster52 100 12 40 35
Butcher12 e 16 23 17
Inahara20 94 6 25 25
Melliere31 e 9 17 23
Naylor34 e e e e
Hsiang19 86 11 33 29
Oertli36 e e e e
Oskam38 e e e e
Radoux44 91 10 27 43
Vitale50 88 12 32 52
All studies 95 11 29 32
464 K.W.H. Chiu et al.data were presented in life-table formats. In the remaining
studies, life-tables were reconstructed from survival curves
with sufficient data. We assumed that the lowest point at
each time interval in a survival curve represented the
patency rate of the observed unit at that time.Table 8 Short and long-term outcomes for Aortofemoral Bypas
Author Early morbidity
Operative morality (%) Systemic (%)
Bowes10 7.7 4.2
Brewster52 2.6 e
Couch14 1.0 16.1
Dunn15 3.1 17.2
Friedman16 0.0 8.3
Harris18 3.5 e
Jackson21 1.6 19.4
Jensen22 0.0 5.4
Johnson23 5.7 e
Lau26 8.7 e
Littooy27 4.9 4.0
Martinez28 5.6 25.3
Mason29 6.8 30.5
Meister30 2.0 14.0
Melliere31 0.9 e
Mingoli32 3.4 3.8
Mulcare33 8.8 e
Naylor34 e e
Hsiang19 e e
Passman39 0.7 19.4
Piotrowski41 3.0 13.0
Prager42 4.0 e
Prediville43 3.0 e
Schneider45 0.8 e
Sladen46 0.0 e
Szilagy47 5.0 18.0
Timaran48 e 5.0
Van der Vliet49 4.9 13.4
Yamazaki51 11.1 e
All AFB studies 4.1 16.0Patient demographics and risk factors from each study
were pooled for analysis. Statistical comparison of aggre-
gated patency data was based on Cox proportional hazard
regression. Spearman correlation was used to quantify the
association of each of the outcomes with patient demo-
graphics and risk factors. Life-table analysis was carried
out. A covariate, symptomatic status of patients prior to
interventions, was included for further sub-analysis using
methodology previously described by Hunink and Wong.8
This methodology allows the combination of failure-time
data from various sources, adjusting for differences in
case-mix among studies. It is based on the proportional-
hazards model and the actuarial life-table approach. Two-
sided p-values are reported and differences in results were
considered to be ‘‘statistically significant’’ if the p-value
was <0.05. Microsoft Excel 2000 and the statistical
package Graphpad Prism version 5.00 were utilised for
analysis.
Results
590 studies were identified, 331 (56%) studies were
excluded from their abstracts alone, resulting in 259 (44%)
articles being retrieved. A further 214 (36%) publicationss studies.
Local (%) Graft related (%) 5-year patency rate
e 3.8 92.0
e 1.2 90.5
e e e
3.1 5.7 86.0
11.7 0.0 95.5
e e 91.0
21.0 3.6 78.0
14.3 3.6 e
e e 76.9
e e 89.0
9.8 4.5 87.6
4.0 0.5 88.3
5.2 3.6 e
14.0 e 91.8
0.0 3.7 82.0
6.7 2.5 82.5
e 5.3 e
e e 92.8
e e 86.5
12.4 1.4 74.0
22.0 e 97.0
e e 89.0
e e 90.5
e 4.2 62.5
e 2.0 83.0
4.3 3.7 85.3
1.7 1.7 86.0
8.0 e 86.4
e 3.7 85.9
6.3 3.1 86.3
Table 9 Short and long-term outcomes for Iliofemoral Bypass studies.
Author Early morbidity
Operative morality (%) Systemic (%) Local (%) Graft related (%) 5-year patency rate
Cham13 1.9 e e e 86.0
Harrington17 2.9 e e 4.4 73.4
Jorgensen24 5.0 e e e 83.0
Kalman25 0.0 e e e e
Mason29 0.0 11.1 e e e
Melliere55 1.4 e 0.7 2.1 73.0
Ng35 5.6 35.7 11.0 9.3 75.0
Oliveira37 12.5 e 6.3 e 64.0
Perler40 9.0 16.9 14.0 0.0 88.0
Piotrowski41 0.0 18.0 6.0 e 48.0
Van der Vliet49 1.6 11.4 7.0 e 87.9
All studies 2.7 18.9 5.7 4.2 85.3
Surgical Management of Atherosclerotic Aorto-Iliac Occlusive Disease 465were excluded for various reasons. Thus, 45 (8%) articles
were included in the process of data extraction and analysis
(Fig. 3).4,5,9e51
Of the 45 studies included, 29 studies (5738 patients)
included data for AFB, 11 studies (778 patients) for IFB and
11 studies (1490 patients) for AIE. Two studies (174
patients) were identified for DTAF.4,5 Six studies included
data for both AFB and IFB and one study included data for
AFB, IFB and AIE19,29,34,41,49,52 (Tables 1e7).
More patients underwent AFB than AIE or IFB. The
majority of these patients were male (76.5%) and their
main indication for intervention was intermittent claudi-
cation (IC). There were significant inter-study differences
for patient demographics and risk factors: male:female
ratio (p< 0.02), smoking history, diabetes, ischaemic heart
disease (IHD) and hypertension (HT) (all p< 0.0001). The
AFB cohort had the highest proportion of patients with
diabetes and HT while the IFB cohort had the highest
proportion of patients with IHD and CLI as the indication for
surgery. The AIE cohort had the highest proportion of
smokers. There were insufficient data to analyse mean age
between the cohorts (Table 1).Table 10 Short and long-term outcomes for Aortoiliac Endarter
Author Early morbidity
Operative morality (%) Systemic (%)
Aguiar9 4.2 e
Brewster52 5.0 e
Butcher12 6.0 24.0
Hsiang19 e e
Inahara20 5.0 15.0
Melliere31 2.8 e
Naylor34 0.0 9.0
Oertli36 1.2 e
Oskam38 0.0 10.3
Radoux44 0.0 4.0
Vitale50 0.0 5.3
All studies 2.7 12.5The operative mortality rate for AFB, IFB and AIE was
reported in 93% (42/45) of the studies and was 4.1%, 2.7%
and 2.7%, respectively (p< 0.0001). Systemic morbidity
was reported in 56% (25/45) of studies, local morbidity in
51% (23/45) and graft-related morbidity/failed endarter-
ectomy in 71% (32/45). The systemic morbidity rate was
16% for AFB, 18.9% for IFB and 12.5% for AIE (p< 0.0001).
The local morbidity rate was 6.3% for AFB, 5.7% for IFB and
3.4% for AIE (p< 0.003). There was no correlation between
operative mortality and systemic or local morbidity, and
patient demographics or risk factors. The graft-related
morbidity/intervention failure rates for AFB, IFB and AIE
were 3.1%, 4.2% and 3.8%, respectively (pZ 0.31). For
AFB, 8 studies (2619 patients) quoted graft infection rates
and the combined rate was calculated to be 0.7%. As for
IFB, only 3 studies (237 patients) mentioned graft infec-
tion rates specifically and was calculated to be 0.4%.
There are insufficient data to analysis the severity of these
infections.
Patency criteria were defined in 58% (26/45) of studies
and these varied from clinical symptomatology/examina-
tion to radiological assessment. All studies except one23ectomy studies.
Local (%) Failed AIE (%) 5-year patency rate
e 18.3 87.0
e 3.7 86.8
2.0 4.0 72.0
e e 82.0
2.0 2.2 92.0
2.8 2.8 92.0
5.3 3.5 92.0
e 2.7 93.5
2.1 3.2 83.0
6.1 6.1 78.9
6.7 0.0 80.4
3.4 3.8 88.3
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AFB 
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AIE 
Claudication 1397 1287 1153 1034 911 806 721 639 566 503 439
AIE 
Ischaemia 574 511 449 393 339 296 259 226 197 172 147
IFB 
Claudication 416 344 264 217 169 144 118 105 88 78 67
IFB 
Ischaemia 373 288 212 170 131 109 87 76 64 56 47
Figure 2 Patency rates for patients undergoing Aortofemoral Bypass, Iliofemoral Bypass and Aortoiliac Endarterectomy for
intermittent claudication and critical limb ischaemia.
Potentially relevant Studies identified 
and screened for retrieval 
n = 590
Studies retrieved for more detailed 
evaluation  
n = 259 
Studies excluded n = 331 
Unrelated to open anatomical surgical 
repair n = 151 
Reviews n = 64 
Studies with <10 patients n = 116
Studies included in analysis 
n = 45 
Studies with usable information, by 
outcome:  
Aortofemoral bypass n = 29*  
Iliofemoral bypass n = 11* 
Endarterectomy n = 11* 
Descending Thoracic Aortofemoral 
bypass n = 2* 
*6 studies had data suitable for extraction 
for 2 procedures and 1 had data suitable 
for extraction for 3 procedures
Studies excluded from analysis  
n = 214
Studies not providing enough data to 
distinguish selected interventions from 
other interventions n = 106 
Interventions not done for aortoiliac 
occlusive disease n = 10 
Data included in other publications  
n = 24 
Studies with <10 patients for the specific 
intervention n = 2  
Unable to construct life-table from study 
n = 72
Figure 3 Data selection.
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Surgical Management of Atherosclerotic Aorto-Iliac Occlusive Disease 467reported primary patency data. Although Johnson et al.23
reported secondary patency in isolation we were able to
reconstruct a primary patency life-table from the published
data. The 5-year primary patency rates were 86.3%, 85.3%
and 88.3% for AFB, IFB and AIE, respectively (pZ 0.12).
Outcomes following AFB, IFB and AIE were further sub-
analysed according to patient clinical presentation. The 5-
year primary patency rates for patients with IC were 89.8%,
86.7% and 90.8% for AFB, IFB and AIE, respectively
(pZ 0.07) and, for patients with CLI, were 79.8%, 74.1%
and 81.7% for AFB, IFB and AIE, respectively (pZ 0.06).
There was a significant difference in 5-year patency rates
for patients with IC and CLI (p< 0.0001) (Tables 1, 8e10
and Figs. 1 and 2).
The pooled results were further analysed according to
the decade during which the studies were undertaken. For
AFB, the 5-year patency in studies carried out during the
1970s was 88.4% and gradually decreased to 76.1% for
studies carried out after the millennium (pZ 0.03). For IFB,
data were only available for studies carried out in the 1980s
and 1990s and this also demonstrated a fall in 5-year
patency rate from 88.6% to 73.1% (pZ 0.001). The results
were not statistically significant for AIE.
The small number of patients who underwent DTAF
precluded reliable statistical comparison with the other
three techniques. Operative mortality for DTAF was 4.6%.
Systemic and local morbidities were not reported in the
published studies but graft-related morbidity was 4.5%. The
5-year primary patency rate for DTAF was 79.6% (Table 11).T
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5Discussion
The present review represents more than 35 years of
experience in anatomical open surgical revascularisation
for patients with symptomatic AIOD and, to our knowledge,
the first comparative analysis of major outcomes following
aortofemoral bypass, iliofemoral bypass and aortoiliac
endarterectomy.
The principal finding of the present study is that AIE
appears to be associated with significantly lower operative
mortality (2.7%) and systemic (12.5%) and local complica-
tion rates (3.3%) compared with the two bypass procedures.
The reason for this finding is not obvious from the data
collected and presented but intuitively one would assume
that patient selection is important with AIE being utilised
predominantly for localised aortoiliac disease and AFB and
IFB may be used for more extensive disease.53 All three
techniques were equally effective in terms of 5-year
primary patency rates. There was a trend toward improved
5-year patency rates for both IC and CLI following AFB and
AIE when compared to IFB.
Several studies have compared prosthetic bypass with
endarterectomy for the treatment of AOID with conflicting
results. Some authors have reported higher morbidity and
lower patency rates for AIE52,54 while others have demon-
strated lower morbidity and comparable long-term
outcomes when compared with bypass in appropriately
selected patients.53,55,56 There are no trials directly
comparing AFB and IFB, and those observational studies
that exist are inconclusive with some reporting comparable
outcomes while others report poorer long-term outcomes
Table 12 Study design and reported results of Aortofemoral Bypass studies.
Author Type of Study Retrospective/
Prospective
Materials used Unit of
observation
Source
of data
Patency
reported
Bowes10 Observation Retrospective Not mentioned Limb Figure Primary
Brewster52 Observation Retrospective Not mentioned Limb Table Primary
Couch14 Observation Retrospective Dacron/PTFE Limb Figure Primary
Dunn15 Observation Retrospective Not mentioned Patient Table Primary
Friedman16 Randomised Prospective Dacron/PTFE Limb Table Primary
Harris18 Observation Retrospective Dacron Limb Figure Primary
Jackson21 Observation Retrospective SFP vein/Dacron Patient Table Primary
Jensen22 Observation Retrospective Not mentioned Patient Table Primary
Johnson23 Observation Retrospective Dacron Patient Table Secondary
Lau26 Observation Retrospective Dacron Limb Figure Primary
Littooy27 Observation Retrospective Dacron Limb Table Primary
Martinez28 Observation Retrospective Dacron Limb Table Primary
Mason29 Observation Retrospective Dacron/PTFE Limb Figure Primary
Meister30 Randomised Prospective Not mentioned Patient Figure Primary
Melliere31 Observation Prospective Dacron/PTFE/SFP vein Patient Table Primary
Mingoli32 Observation Retrospective Not mentioned Limb Figure Primary
Mulcare33 Observation Retrospective Not mentioned Patient Table Primary
Naylor34 Observation Retrospective Not mentioned Both Figure Primary
Hsiang19 Observation Retrospective Not mentioned Patient Figure Primary
Passman39 Observation Retrospective PTFE Patient Table Primary
Piotrowski41 Observation Retrospective Not mentioned Patient Figure Primary
Prager42 Randomised Prospective Dacron/PTFE Patient Figure Primary
Prediville43 Observation Retrospective Dacron Limb Figure Primary
Schneider45 Observation Retrospective Dacron/PTFE Patient Figure Primary
Sladen46 Observation Retrospective Not mentioned Patient Table Primary
Szilagy47 Observation Retrospective Dacron/others Patient Table Primary
Timaran48 Observation Retrospective PTFE/polyester Patient Figure Primary
Van der Vliet49 Observation Retrospective Dacron/PTFE Patient Table Primary
Yamazaki51 Observation Retrospective PTFE Patient Table Primary
468 K.W.H. Chiu et al.with IFB.17,25,41,57 However, IFB is consistently reported as
being less traumatic and requiring shorter exposure time
when compared to AFB.13,58
As expected, patients presenting with CLI demonstrated
poorer 5-year patency rates when compared with patients
with IC irrespective of reconstruction.7,34,59,60 Unfortu-
nately, there was insufficient breakdown of published data
to perform sub-analysis according to patient characteris-
tics, risk factors and operative risks.Table 13 Study design and reported results of Iliofemoral Bypa
Author Type of Study Retrospective/
Prospective
Mater
Cham13 Observation Retrospective Dacro
Harrington17 Observation Retrospective Dacro
Jorgensen24 Observation Retrospective Not m
Kalman25 Observation Retrospective Not m
Mason29 Observation Retrospective Dacro
Melliere55 Observation Prospective Dacro
Ng35 Observation Retrospective Not m
Oliveira37 Observation Retrospective Not m
Perler40 Observation Retrospective Dacro
Piotrowski41 Observation Retrospective Not m
Van der Vliet49 Observation Retrospective DacroInterestingly, when data were compared by decade of
publication there was a decrease in patency rates for AFB
and IFB over time. Previous studies have shown either no
statistical difference or improved patency over time.7,52,61
When each of the patient characteristics were analysed
there were statistical differences over time, but no obvious
trend to explain why patency rates fell with time. For AFB,
patients were younger, more presented with CLI, systemic
morbidity fell, local morbidity increased and operativess studies.
ials used Unit of
observation
Source
of data
Patency
reported
n/PTFE Limb Figure Primary
n/PTFE Patient Table Primary
entioned Limb Figure Primary
entioned Patient Figure Primary
n/PTFE Limb Figure Primary
n/PTFE/SFP vein Patient Table Primary
entioned Patient Figure Primary
entioned Patient Figure Primary
n/PTFE Patient Figure Primary
entioned Patient Figure Primary
n/PTFE Patient Table Primary
Table 14 Study design and reported results of Aortoiliac Endarterectomy studies.
Author Type of Study Retrospective/Prospective Unit of
Observation
Source
of data
Patency
reported
Aguiar9 Observation Prospective Patient Figure Primary
Brewster52 Observation Retrospective Limb Table Primary
Butcher12 Observation Retrospective Patient Table Primary
Hsiang19 Observation Retrospective Patient Figure Primary
Inahara20 Observation Prospective Limb Table Primary
Melliere31 Observation Retrospective Patient Table Primary
Naylor34 Observation Retrospective Limb Figure Primary
Oertli36 Observation Retrospective Limb Figure Primary
Oskam38 Observation Retrospective Limb Figure Primary
Radoux44 Observation Retrospective Limb Table Primary
Vitale50 Observation Retrospective Limb Table Priamry
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those observed by de Vries and colleagues with the
exception that we did not reveal a statistically significant
change in mortality rate.7 As for IFB, patients were similar
in age, less likely to have CLI, systemic morbidity rose, and
minor morbidity and mortality remained unchanged. A
factor to consider when analysing these results is that there
may be overlaps between decades when the operations
were carried out. We aggregated our results depending on
when the studies were published.
The majority of these studies are retrospective obser-
vational studies with the exception of two prospective
observational studies9,31and 3 randomised trials.16,30,42 As
none of the patients nor surgeons involved in any of the
studies were blinded, these data may be biased. Although it
is difficult to minimise problems such as selection, perfor-
mance and detection bias as patients selected into the
studies involved were determined by the authors of the
studies, we attempted to minimise the effect by selecting
studies with larger groups (i.e. studies involving more than
10 patients). We further attempted to minimise analysis
bias by carrying out our statistical analysis by an external
statistician with no prior knowledge in any of the tech-
niques or preferences of the other authors.
Nearly half of the studies did not mention the types of
grafts used in their studies. The majority of the remainder
used a combination of Dacron and PTFE, while others used
only Dacron, PTFE or superficial femoral vein. Amongst the
studies that use a combination of graft materials, only 3
studies provided sufficient data to allow different types of
grafts used to be separately analysed (Tables 12e14).16,42,48
Thus further analysis on how different types of grafts affect
patency were not carried out.
Only two studies reporting results for DTAF were iden-
tified as suitable for data extraction.4,5 As one might
expect, these data suggest that DTAF is associated with
higher operative mortality and graft-related complication
rates and lower 5-year patency rate than the other three
techniques. However, as DTAF was not included in the
statistical analysis it is difficult to draw robust
conclusions.
In conclusion, the present review demonstrates that AIE
is associated with significantly lower morbidity and
mortality rates and equivalent patency rates to AFB andIFB. In appropriately selected patients AIE remains an
acceptable, relatively low-risk and robust reconstruction.
In patients who do not have a pattern of disease amenable
to endarterectomy, AFB or IFB can provide equally effec-
tive long-term outcomes albeit with higher peri-operative
risk. These data provide an important benchmark with
which to compare the short- and long-term results of
emerging endovascular interventions.
Conflict of Interest
None.
Funding
None.
References
1 Dormandy JA, Rutherford RB. Management of peripheral arte-
rial disease (PAD). TASC working Group. TransAtlantic inter-
Society Consensus (TASC). J Vasc Surg 2000 Jan;31(1 Pt 2):S1e
S296.
2 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA,
Fowkes FG. Inter-Society Consensus for the management of
peripheral arterial disease (TASC II). J Vasc Surg 2007 Jan;
45(Suppl. S):S5eS67.
3 Brewster DC. Current controversies in the management of
aortoiliac occlusive disease. J Vasc Surg 1997 Feb;25(2):365e
79.
4 Criado E, Johnson Jr G, Burnham SJ, Buehrer J, Keagy BA.
Descending thoracic aorta-to-iliofemoral artery bypass as an
alternative to aortoiliac reconstruction. J Vasc Surg 1992 Mar;
15(3):550e7.
5 Schultz RD, Sterpetti AV, Feldhaus RJ. Thoracic aorta as source
of inflow in reoperation for occluded aortoiliac reconstruction.
Surgery 1986 Oct;100(4):635e45.
6 Cacoub P, Godeau P. Risk factors for atherosclerotic aortoiliac
occlusive disease. Ann Vasc Surg 1993 Jul;7(4):394e405.
7 de Vries SO, Hunink MG. Results of aortic bifurcation grafts for
aortoiliac occlusive disease: a meta-analysis. J Vasc Surg 1997
Oct;26(4):558e69.
8 Hunink MG, Wong JB. Meta-analysis of failure-time data with
adjustment for covariates. Med Decis Making 1994 Jan;14(1):
59e70.
470 K.W.H. Chiu et al.9 Aguiar ET, Lederman A, Sitrangulo Jr CJ, Puech-Leao P. Aorto-
femoral thromboendarterectomy. Rev Hosp Clin Fac Med Sao
Paulo 2002 Jul;57(4):147e60.
10 Bowes DE, Youkey JR, Franklin DP, Benoit CH, Pharr WF. An
algorithm for the surgical management of chronic abdominal
aortic occlusion and occluded aortofemoral grafts. J Cardiovasc
Surg (Torino) 1992 Nov;33(6):650e9.
11 Brewster DC, Meier III GH, Darling RC, Moncure AC,
LaMuraglia GM, Abbott WM. Reoperation for aortofemoral graft
limb occlusion: optimal methods and long-term results. J Vasc
Surg 1987 Feb;5(2):363e74.
12 Butcher Jr HR, Jaffe BM. Treatment of aortoiliac arterial
occlusive disease by endarterectomy. Ann Surg 1971 Jun;
173(6):925e32.
13 Cham C, Myers KA, Scott DF, Devine TJ, Denton MJ. Extraper-
itoneal unilateral iliac artery bypass for chronic lower limb
ischaemia. Aust N Z J Surg 1988 Nov;58(11):859e63.
14 Couch NP, Clowes AW, Whittemore AD, Lombara JA,
Henderson BA, Mannick JA. The iliac-origin arterial graft:
a useful alternative for iliac occlusive disease. Surgery 1985
Jan;97(1):83e7.
15 Dunn DA, Downs AR, Lye CR. Aortoiliac reconstruction for
occlusive disease: comparison of end-to-end and end-to-side
proximal anastomoses. Can J Surg 1982 Jul;25(4):382e4.
16 Friedman SG, Lazzaro RS, Spier LN, Moccio C, Tortolani AJ.
A prospective randomized comparison of Dacron and poly-
tetrafluoroethylene aortic bifurcation grafts. Surgery 1995 Jan;
117(1):7e10.
17 Harrington ME, Harrington EB, Haimov M, Schanzer H,
Jacobson JH. Iliofemoral versus femorofemoral bypass: the case
for an individualized approach. J Vasc Surg 1992 Dec;16(6):
841e52.
18 Harris PL, Bigley DJ, McSweeney L. Aortofemoral bypass and the
role of concomitant femorodistal reconstruction. Br J Surg 1985
Apr;72(4):317e20.
19 Hsiang Y, Hildebrand HD. Results of vascular surgery in younger
versus older patients. Am J Surg 1989 Apr;157(4):419e22.
20 Inahara T. Eversion endarterectomy for aortoiliofemoral
occlusive disease. A 16 year experience. Am J Surg 1979 Aug;
138(2):196e204.
21 Jackson MR, Ali AT, Bell C, Modrall JG, Welborn III MB,
Scoggins E, et al. Aortofemoral bypass in young patients with
premature atherosclerosis: is superficial femoral vein superior
to Dacron? J Vasc Surg 2004 Jul;40(1):17e23.
22 Jensen BV, Egeblad K. Aorto-iliac arteriosclerotic disease in
young human adults. Eur J Vasc Surg 1990 Dec;4(6):583e6.
23 Johnson WC, LoGerfo FW, Vollman RW, Corson JD, O’Hara ET,
Mannick JA, et al. Is axillo-bilateral femoral graft an effective
substitute for aortic-bilateral iliac/femoral graft?: an analysis
of ten years experience. Ann Surg 1977 Aug;186(2):123e9.
24 Jorgensen PE, Lundsgaard C, Jelnes R, Frimodt-Moller C. Ilio-
femoral bypass surgery for lower limb ischaemia. A follow-up of
62 patients. Ann Chir Gynaecol 1986;75(3):155e9.
25 Kalman PG, Hosang M, Johnston KW, Walker PM. Unilateral iliac
disease: the role of iliofemoral bypass. J Vasc Surg 1987 Aug;
6(2):139e43.
26 Lau H, Cheng SW. Long-term outcome of aortofemoral bypass
for aortoiliac occlusive disease. Ann Acad Med Singapore 2000
Jul;29(4):434e8.
27 Littooy FN, Steffan G, Steinam S, Saletta C, Greisler HP. An
11-year experiencewith aortofemoral bypass grafting.Cardiovasc
Surg 1993 Jun;1(3):232e8.
28 Martinez BD, Hertzer NR, Beven EG. Influence of distal arterial
occlusive disease on prognosis following aortobifemoral bypass.
Surgery 1980 Dec;88(6):795e805.
29 Mason RA, Smirnov VB, Newton GB, Giron F. Alternative
procedures to aortobifemoral bypass grafting. J Cardiovasc Surg
(Torino) 1989 Mar;30(2):192e7.30 Meister RH, Schweiger H, Lang W. Knitted double-velour Dacron
prostheses in aortobifemoral positionelong-term performance
of different coating materials. Vasa 1998 Nov;27(4):236e9.
31 Melliere D, Labastie J, Becquemin JP, Kassab M, Paris E. Prox-
imal anastomosis in aortobifemoral bypass: end-to-end or end-
to-side? J Cardiovasc Surg (Torino) 1990 Jan;31(1):77e80.
32 Mingoli A, Sapienza P, Feldhaus RJ, Di ML, Burchi C, Cavallaro A.
Aortoiliofemoral bypass graft in young adults: long-term results in
a series of sixty-eight patients. Surgery 1997 Jun;121(6):646e53.
33 Mulcare RJ, Royster TS, Lynn RA, Conners RB. Long-term results
of operative therapy for aortoiliac disease. Arch Surg 1978 May;
113(5):601e4.
34 Naylor AR, Ah-See AK, Engeset J. Morbidity and mortality after
aortofemoral grafting for peripheral limb ischaemia. J R Coll
Surg Edinb 1989 Aug;34(4):215e8.
35 Ng RL, Gillies TE, Davies AH, Baird RN, Horrocks M. Iliofemoral
versus femorofemoral bypass: a 6-year audit. Br J Surg 1992
Oct;79(10):1011e3.
36 Oertli D, Wigger P, Landmann J, Waibel P. Long-term results
after open and semiclosed thrombendarterectomy for aortoiliac
occlusive disease. Eur J Vasc Endovasc Surg 1996 May;11(4):
432e6.
37 Oliveira M, Wilson SE, Williams R, Freischlag JA. Iliofemoral
bypass: a 10-year review. Cardiovasc Surg 1993 Apr;1(2):103e6.
38 Oskam J, van den Dungen JJ, Boontje AH. Thromboendarter-
ectomy for obstructive disease of the common iliac artery.
Cardiovasc Surg 1996 Jun;4(3):356e9.
39 Passman MA, Taylor LM, Moneta GL, Edwards JM, Yeager RA,
McConnell DB, et al. Comparison of axillofemoral and aortofe-
moral bypass for aortoiliac occlusive disease. J Vasc Surg 1996
Feb;23(2):263e9.
40 Perler BA, Burdick JF, Williams GM. Femoro-femoral or ilio-
femoral bypass for unilateral inflow reconstruction? Am J Surg
1991 Apr;161(4):426e30.
41 Piotrowski JJ, Pearce WH, Jones DN, Whitehill T, Bell R, Patt A,
et al. Aortobifemoral bypass: the operation of choice for
unilateral iliac occlusion? J Vasc Surg 1988 Sep;8(3):211e8.
42 Prager MR, Hoblaj T, Nanobashvili J, Sporn E, Polterauer P,
Wagner O, et al. Collagen- versus gelatine-coated Dacron versus
stretch PTFE bifurcation grafts for aortoiliac occlusive disease:
long-term results of a prospective, randomized multicenter
trial. Surgery 2003 Jul;134(1):80e5.
43 Prendiville EJ, Burke PE, Colgan MP, Wee BL, Moore DJ,
Shanik DG. The profunda femoris: a durable outflow vessel in
aortofemoral surgery. J Vasc Surg 1992 Jul;16(1):23e9.
44 Radoux JM, Maiza D, Coffin O. Long-term outcome of 121 ilio-
femoral endarterectomy procedures. Ann Vasc Surg 2001 Mar;
15(2):163e70.
45 Schneider JR, Besso SR, Walsh DB, Zwolak RM, Cronenwett JL.
Femorofemoral versus aortobifemoral bypass: outcome and
hemodynamic results. J Vasc Surg 1994 Jan;19(1):43e55.
46 Sladen JG, Gilmour JL, Wong RW. Cumulative patency and
actual palliation in patients with claudication after aortofe-
moral bypass. Prospective long-term follow-up of 100 patients.
Am J Surg 1986 Aug;152(2):190e5.
47 Szilagyi DE, Elliott Jr JP, Smith RF, Reddy DJ, McPharlin M. A
thirty-year survey of the reconstructive surgical treatment of
aortoiliac occlusive disease. J Vasc Surg 1986 Mar;3(3):421e36.
48 Timaran CH, Stevens SL, Freeman MB, Goldman MH. Infrain-
guinal arterial reconstructions in patients with aortoiliac
occlusive disease: the influence of iliac stenting. J Vasc Surg
2001 Dec;34(6):971e8.
49 van der Vliet JA, Scharn DM, de Waard JW, Roumen RM, van
Roye SF, Buskens FG. Unilateral vascular reconstruction for iliac
obstructive disease. J Vasc Surg 1994 Apr;19(4):610e4.
50 Vitale GF, Inahara T. Extraperitoneal endarterectomy for
iliofemoral occlusive disease. J Vasc Surg 1990 Oct;12(4):
409e13.
Surgical Management of Atherosclerotic Aorto-Iliac Occlusive Disease 47151 Yamazaki I, Karube N, Soma T, Noishiki Y, Ichikawa Y. Long-term
outcomes using vascular grafts sealed with fragmented autol-
ogous adipose tissue for aortoiliac occlusive disease. J Artif
Organs 2005;8(1):67e70.
52 Brewster DC, Darling RC. Optimal methods of aortoiliac recon-
struction. Surgery 1978 Dec;84(6):739e48.
53 Connolly JE, Price T. Aortoiliac endarterectomy: a lost art? Ann
Vasc Surg 2006 Jan;20(1):56e62.
54 Gaspard DJ, Cohen JL, Gaspar MR. Aortoiliofemoral throm-
boendarterectomy vs bypass graft. A randomized study. Arch
Surg 1972 Dec;105(6):898e901.
55 Melliere D, Blancas AE, Desgranges P, Becquemin JP. The
underestimated advantages of iliofemoral endarterectomy. Ann
Vasc Surg 2000 Jul;14(4):343e9.
56 Urayama H, Ohtake H, Yokoi K, Fujimori H, Kawaguchi M,
Ishikawa T, et al. Long-term results of endarterectomy,
anatomic bypass and extraanatomic bypass for aortoiliac
occlusive disease. Surg Today 1998;28(2):151e5.57 Kram HB, Gupta SK, Veith FJ, Wengerter KR. Unilateral aorto-
femoral bypass: a safe and effective option for the treatment of
unilateral limb-threatening ischemia. Am J Surg 1991 Aug;
162(2):155e8.
58 Zukauskas G, Ulevicius H, Janusauskas E. An optimal inflow
procedure for multi-segmental occlusive arterial disease: ilio-
femoral versus aorto-bifemoral bypass. Cardiovasc Surg 1998
Jun;6(3):250e5.
59 Nevelsteen A, Suy R. Graft occlusion following aortofemoral
Dacron bypass. Ann Vasc Surg 1991 Jan;5(1):32e7.
60 van den Akker PJ, van Schilfgaarde R, Brand R, van Bockel JH,
Terpstra JL. Long term success of aortoiliac operation for
arteriosclerotic obstructive disease. Surg Gynecol Obstet 1992
Jun;174(6):485e96.
61 Nevelsteen A, Wouters L, Suy R. Long-term patency of the
aortofemoral Dacron graft. A graft limb related study over
a 25-years period. J Cardiovasc Surg (Torino) 1991 Mar;32(2):
174e80.
